Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AF 102B; Cevimeline hydrochloride; Evoxac; FKS 508; Saligren; SND 5088; SNI 2011; SNK 508

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Israel Institute for Biological Research
  • Developer Daiichi Sankyo Company; Nippon Kayaku; SnowBrand Pharmaceuticals
  • Class Quinuclidines; Small molecules; Thiophenes
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Xerostomia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Oct 2012 Authorised generic equivalent available in USA
  • 27 Aug 2007 No development reported - Clinical-Phase-Unknown for Dry eyes in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top